LYMPHIR Gains Momentum as Citius Oncology Builds a Strong CTCL Launch

Key Points

• Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL).
• New U.S. institutions ordering LYMPHIR rose 78% quarter over quarter, with total vials ordered increasing 31%.
• LYMPHIR now has near‑universal payer coverage and is available at 42 institutions, including leading academic centers and NCCN member sites.

Citius Oncology, Inc. (Nasdaq: CTXR) is highlighting strong early progress for LYMPHIR, its cancer treatment for adults with relapsed or refractory CTCL. The company’s latest commercial update shows that more hospitals and infusion centers are ordering the drug, payers are broadly covering it, and the launch continues to gather momentum as LYMPHIR becomes more established in the CTCL treatment landscape.

Growing adoption across U.S. cancer treatment centers

In the quarter ended June 30, 2026, new institutions ordering LYMPHIR from wholesalers increased 78% compared with the prior quarter, while total vials ordered by institutions rose 31%. LYMPHIR is now being ordered through wholesalers by 42 institutions nationwide, including major academic oncology centers, National Comprehensive Cancer Network (NCCN) member sites, and community infusion centers. Subsequent wholesaler orders have increased in size to match demand, suggesting that use is shifting from initial stocking toward ongoing treatment of patients.

Formulary approvals and payer coverage expand access

Citius Oncology reports that formulary reviews and approvals for LYMPHIR continue to advance at priority centers, giving more physicians the ability to prescribe and administer the drug. At the same time, LYMPHIR has achieved near‑universal coverage across commercial health plans, with the company noting no denials to date for patients who meet the label criteria. This combination of formulary inclusion and robust reimbursement underpins broader access and supports continued growth in use.

Early revenue and launch metrics reflect a strengthening base

Since LYMPHIR’s launch in December 2025, Citius Oncology has reported $3.9 million in initial launch revenue for the quarter ended December 31, 2025 and $5.6 million in net revenue for the first half of fiscal 2026, at gross margins around 80%. The company also noted that a large majority of its targeted institutions—about 83%—have either added LYMPHIR to formulary or are actively reviewing it. Taken together, these indicators point to a launch that is gaining traction as awareness and experience with the drug expand.

Market opportunity for LYMPHIR in CTCL

LYMPHIR is approved for adults with relapsed or refractory Stage I–III CTCL who have received at least one prior systemic therapy, a patient group with limited options and significant unmet need. Citius Oncology estimates that the current CTCL market opportunity for LYMPHIR exceeds $400 million and is growing. As more centers adopt the drug and coverage remains strong, LYMPHIR is positioned to play a larger role in CTCL care and to potentially drive continued growth for Citius Oncology.